

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 April 2024 (11.04.2024)



(10) International Publication Number
WO 2024/074959 A1

(51) International Patent Classification:

A61K 31/4166 (2006.01) A61K 45/06 (2006.01)
A61K 31/5025 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2023/059790

(22) International Filing Date:

29 September 2023 (29.09.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/412,520	02 October 2022 (02.10.2022)	US
63/434,465	21 December 2022 (21.12.2022)	US
63/445,886	15 February 2023 (15.02.2023)	US
63/470,761	02 June 2023 (02.06.2023)	US

(71) Applicants: **PFIZER INC.** [US/US]; 66 Hudson Boulevard East, New York, New York 10001-2192 (US). **ASTELLAS PHARMA INC.** [JP/JP]; 2-5-1 Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411 (JP).

(72) Inventors: **CZIBERE, Akos Gabor**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **KENNEDY, Dana Ann**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **KOEHLER, Maria Teresa**; 19 Shirley Road, Narberth, Pennsylvania 19072 (US). **MEECH, Sandra Jean**; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US). **WANG, Fong**; 140 Waldo Avenue, Piedmont, California 94611 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., 100 Route 206 North, Mail Stop: SOM-PPK4-LLA-403, Peapack, New Jersey 07977 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE



WO 2024/074959 A1

(54) Title: COMBINATION OF TALAZOPARIB AND ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

(57) Abstract: This invention relates to talazoparib, or a pharmaceutically acceptable salt thereof, in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, for the treatment of metastatic castration-resistant prostate cancer and methods of increasing survival thereof.